ABSTRACT
analogues insulin is similar to human insulin but have differences in cell structure that leading to differences in characteristics of pharmacodynamics and pharmacokinetics. A systematic review of published studies between 2009 until June 2010 in Cochrane Library [CENTRAL and Cochrane Systematic Reviews], DARE, NHS EEDs, and CRD databases were searched. Only nine articles were identified to be included in this review. Most of these studies demonstrated that there were no more or less risks caused by rapid acting insulin compared with human insulin in terms of safety. The risk of sever hypoglycemia significantly, reduced by using long acting insulin analogue. Although it has been shown that insulin analogues are not cost effective, some of these studies pointed out that that insulin Aspart 30 compared with other analogues has more cost effectiveness. Although this type of insulin seems very effective for patients with diabetes, due to the less cost effectiveness in comparison to human insulin, it is recommended that government's resources for this technology will be allocated just to the children and elderly people